Background: Controlling monkeypox effectively requires clinicians have knowledge of monkeypox, attitudes supporting of controlling it, and intentions to adopt practices to address it. Little is known, however, about levels of knowledge, attitudes, and practices (KAPs) in clinician populations in Ohio, United States.
Methods: A cross-sectional, internet-based questionnaire assessed knowledge related to monkeypox, attitudes toward ability to control monkeypox and the threat of monkeypox, and prior relevant practices of having received a smallpox vaccine or having knowledge of monkeypox before 2022, intentions to adopt preventive practices, and demographics. Frequency reporting was used to assess overall knowledge and attitudes. Binary logistic regression was used to predict which KAPs were associated with behavioral intentions.
Results: A total of 197 clinicians participated. No demographic factor was associated with KAPs. Clinicians had relatively poor levels of knowledge. Participants expressed mixed attitudes about eventual control of monkeypox and about threat posed by monkeypox. About one in four participants reported previous knowledge of monkeypox, and about 40 % had received a smallpox vaccine Clinicians reported insufficient levels of intention to adopt preventive practices. Binary regression analysis suggests only perceptions of the threat of monkeypox to public health were associated with intentions to vaccinate self or others.
Conclusions: Educational interventions with clinicians should address inadequate knowledge to support correct diagnosis and treatment. Efforts to enhance the perception of threat of monkeypox to public health may support adherence to preventive recommendations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650995 | PMC |
http://dx.doi.org/10.1016/j.jiph.2022.11.004 | DOI Listing |
Curr Med Res Opin
December 2024
Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Objective: The recent outbreak of monkeypox (mpox) poses significant public health challenges, particularly for immunocompromised populations such as patients with cancer. However, misinformation poses a significant challenge during new outbreaks for patients with chronic diseases, as observed during the COVID-19 pandemic. Therefore, we aimed to assess perspectives and knowledge of patients with cancer on mpox and their willingness to receive mpox vaccination.
View Article and Find Full Text PDFJ Med Virol
December 2024
SR Sanjeevani Hospital, Kalyanpur, Siraha, Nepal.
Mpox, formerly known as monkeypox, has re-emerged as a significant global health concern, particularly during the widespread outbreak of 2022. As an orthopoxvirus related to the eradicated smallpox virus, mpox has been primarily managed with smallpox vaccines and treatments, including the antiviral agent Tecovirimat. This systematic review aims to evaluate the effectiveness and safety of Tecovirimat in treating mpox, focusing on its use during the 2022 outbreak, especially among high-risk populations, including men who have sex with men and people living with HIV.
View Article and Find Full Text PDFPan Afr Med J
December 2024
Department of Global Public Health, Karolinska Institutet, Stockholm, 17177, Sweden.
Cureus
November 2024
Public Health, Health Services Academy, Islamabad, PAK.
Background Monkeypox (Mpox) is a virulent disease caused by orthopoxvirus. Mpox is emerging as a major global health threat. Currently, more than 100 countries are facing outbreaks.
View Article and Find Full Text PDFLancet Infect Dis
November 2024
Rare and Imported Pathogens Laboratory, UKHSA, Porton Down, Salisbury SP4 0JG, UK; Department of Clinical Virology, University College London NHS Hospitals Trust, London, UK. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!